This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In their systematic review and meta-analysis of magnetic resonance spectroscopy (MRS) findings associated with hepatic encephalopathy (HE) due to cirrhosis, Zeng et al. observed a statistically significant increase in glutamine/glutamate metabolites with a decrease in myo-inositol and choline concentrations throughout the parietal, occipital, and basal ganglia regions among patients with HE vs those without HE. Of these metabolites, glutamine/glutamate presence in the parietal lobe was the most robust predictor of HE. In response to these findings, Dr. Gupta expresses concern as to the utility of advanced MRS imaging, given that HE remains a clinical diagnosis. The authors respond that MRS may be useful for earlier identification of mild or subclinical HE, which may lead to earlier, targeted treatment in patients at risk for later decompensation.
In their systematic review and meta-analysis of magnetic resonance spectroscopy (MRS) findings associated with hepatic encephalopathy (HE) due to cirrhosis, Zeng et al. observed a statistically significant increase in glutamine/glutamate metabolites with a decrease in myo-inositol and choline concentrations throughout the parietal, occipital, and basal ganglia regions among patients with HE vs those without HE. Of these metabolites, glutamine/glutamate presence in the parietal lobe was the most robust predictor of HE. In response to these findings, Dr. Gupta expresses concern as to the utility of advanced MRS imaging, given that HE remains a clinical diagnosis. The authors respond that MRS may be useful for earlier identification of mild or subclinical HE, which may lead to earlier, targeted treatment in patients at risk for later decompensation.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Meta-analysis of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy
Expedited Publication
Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex
Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves’ disease